Clinical Trial Update: Safety and Immunogenicity Study for Use of Menactra® Versus Adacel® in Subjects 11 to 55 Years of Age in South Korea [Phase 3]

View source ↗

Summary

Phase 3 safety and immunogenicity trial comparing Menactra to Adacel in individuals aged 11 to 55 in South Korea has completed, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Meningitis
• Meningococcal Disease

Drugs mentioned

• ADACEL (Tdap vaccine (tetanus, diphtheria and acellular pertussis vaccine))
• Menactra (Meningococcal conjugate vaccine (A, C, W, Y))

Snippet

Sponsor: Sanofi Pasteur, a Sanofi Company | Conditions: Meningitis, Meningococcal Disease | Phase 3 | Status: COMPLETED | Results posted: 2013-12-03